An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.

ABSTRACT:

Background

Therapeutic cancer vaccines are an attractive approach for treating malignant tumours, and successful tumour eradication depends primarily on controlling tumour immunosuppression status as well as heterogeneity of tumour cells driven by epigenetic alterations.

Methods

Peptide-loaded dendritic cell (DC) prime and non-infectious peptide booster heterologous immunisations were assessed for the immunogenicity of polo-like kinase-1 (PLK1)-derived peptides. Heterologous vaccination regimen targeting multiple shared tumour antigens simultaneously with PD-L1 blockade was assessed against murine myeloid leukaemia.

Results

A synthetic PLK1₁₂₂ (DSDFVFVVL)-based heterologous vaccination generated large numbers of long-lasting antigen-specific CD8 T-cells eli

SUBMITTER: Shin AR 

PROVIDER: S-EPMC7492404 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature